Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6609 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-25 (law360.com)
Roche Voids Biogen's Protein Production Patent At EPO -
The European Patent Office has stripped Biogen of its protein production patent amid Roche's protests, ruling in a decision released Tuesday that the tech lacks novelty in light of a key ruling from the agency's top appeals panel.
Read more
2024-11-27 (bigmoleculewatch.com)
European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar
On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ. Referencing Regeneron’s biosimilar product EYLEA, OPUVIZ is a 40 mg/mL solution for injection, approved for the treatment of neovascular age related macular degenera...
Read more
2024-11-19 (ritzau.dk)
Samsung Bioepis
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
Read more
2024-11-18 (manilatimes.net)
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ |
OPUVIZ™ is one of the first wave aflibercept biosimilars in Europe
Read more
2024-11-15 (thehindu.com)
EU regulator backs Eisai-Biogen Alzheimer’s drug
EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific patient group.
Read more
2024-06-06 (startmag.it)
The games of Biogen, Genentech, Novartis and Samsung Bioepis seen by the Antitrust
Secondo l'Antitrust, Samsung Bioepis co. Ltd., Samsung Bioepis NL B.V., Biogen Inc., Biogen Italia S.r.l., Genentech Inc., Novartis AG,
Read more
2024-06-06 (fiercepharma.com)
Italy opens antitrust case against Novartis, Roche and others, claiming collusion to delay biosim launch
A new antitrust investigation in Italy has ensnared Novartis, Genentech, Biogen and Samsung Bioepis for allegedly colluding to suppress competition of a Lucentis biosimilar in the country.
Read more
2024-06-06 (ilsalvagente.it)
Antitrust against eight pharmaceutical companies: they favored Lucentis' more expensive drug
Starting from November 2022, the Authority received a series of information from the Italian Medicines Agency relating to the lack of entry
Read more
2024-05-30 (reuters.com)
European Commission grants marketing approval to Biogen's ALS drug |
Biogen said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for its amyotrophic lateral sclerosis (ALS) drug Qalsody.
Read more
2022-02-04 (nikkei.com)
U.S. probes approval of Biogen-Eisai Alzheimer's drug
NEW YORK -- U.S. antitrust and securities regulators are investigating Biogen's conduct involving its controversial Alzheimer's disease trea
Read more
2020-10-22 (informa.com)
Biogen Sees At Least Six Tecfidera Generics And 90% Discounts
Biogen counted the cost of losing its monopoly on Tecfidera in the third quarter, with multiple generic entrants rushing in to the multi-billion-dollar opportunity.
Read more